Helico, an Auckland, New Zealand-based biopharma company, raised AUD $1.8M in Seed funding.
The round was led by Icehouse Ventures, with participation from Custos Privatestiftung, and David Ross.
The company intends to use the funds to extend R&D and staff numbers.
Led by CEO Ilya Vensky, Helico is developing a proprietary computational platform for synthetic biology research using modelling tools and AI-based prediction algorithms. The long-term aim is to develop a seed bank of different drugs able to be licensed to grow medical supplies in confined greenhouses anywhere in the world.
The company is based at the new, deep-tech facility Outset Ventures in Auckland. The facility has GMO-certified labs and Helico has gained New Zealand Environmental Protection Authority approval for R&D using genetically modified organisms.
FinSMEs
18/05/2022